CALGARY, AB,
Feb. 2, 2022 /CNW/ -
Universal Ibogaine Inc. (TSXV: IBO) ("UI" or the
"Company") a life sciences company with a mission to deliver
medicalized ibogaine-centered addiction treatment, has initiated
development plans at its Kelburn treatment facility in preparation
for treatment protocol approval and commencement of ibogaine
treatments.
What is Ibogaine
Ibogaine is a plant derived neuroactive compound that appears to
reset the brains of drug dependent individuals to a pre-addicted
state. Ibogaine has demonstrated particular effectiveness in
treating opioid use disorder. When applied according to a
strict safety protocol, ibogaine appears to eliminate the most
painful symptoms of opioid withdrawal and provides a several month
window free of drug cravings. Dr Alberto Sola, co-founder of Universal Ibogaine
has administered more ibogaine treatments than any other doctor in
the world.
Kelburn Addiction Treatment Center
Universal Ibogaine acquired the licensed and operational Kelburn
Mental Health and Addiction Treatment facility in October of
2021. The facility sits on a destination 50 acre estate with
a 9 hole golf course and currently operates as a traditional
addiction treatment center.
Universal Ibogaine has undertaken plans to expand the facility
to include traditional drug detox and to begin to incorporate the
best in nuovo treatment modalities including Ketamine, Psilocybin
and MDMA assisted psychotherapies.
Universal Ibogaine has commenced development plans to construct
a stand alone ibogaine detox facility on the property in
preparation for the completion of its proof of concept study with
Health Canada.
Dr Ian Rabb – Chief Clinics
Officer
Dr Ian Rabb of Universal Ibogaine
stated: "In my 20 years of addiction treatment, I have not seen
anything with the power and promise of ibogaine to break the cycle
of addiction. When paired with a long term support plan,
which we provide through our Kelburn facility, we expect to
completely disrupt the addiction treatment model. Ibogaine is
legal in Canada under the
prescription drug list and requires a proof of safety trial through
Health Canada. We are sitting on the edge of being able to
tackle the opioid crisis head on."
Drug Supply Update
Universal Ibogaine would also like to provide an update
regarding the drug supply agreement with Psygen. The agreement was
announced prematurely and contained some minor errors regarding the
synthesis of the compound. As a result, the parties to the
agreement have withdrawn.
UI is currently in negotiations with two alternative drug
suppliers.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the
safety and efficacy of its ibogaine based drug detox protocol
through a Canadian Clinical Trial, and ultimately to utilize that
protocol around the globe through future licensing
agreements. UI is concurrently developing a state of the art
holistic addiction treatment protocol at its Kelburn Clinic that,
when paired with the ibogaine detox protocol, is intended to
revolutionize the way we treat addiction and drastically improve
the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This news release may contain forward-looking statements and
information. Forward-looking information is frequently
characterized by words such as "plans", "expect", "project",
"intend", "will", "believe", "anticipate", "estimate", "scheduled",
"potential", or other similar words, or statements that certain
events or conditions "may", "should" or "could" occur. The
forward-looking statements and information are based on certain key
expectations and assumptions made by UI. Although UI
believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements
because UI can give no assurance that they will prove to be
correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to a number of factors and risks, which
include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that
assumptions used in the preparation of such information, although
considered reasonable by UI at the time of preparation, may prove
to be incorrect and readers are cautioned not to place undue
reliance on forward-looking information, which speaks only to
conditions as of the date hereof. UI does not undertake any
obligation to release publicly any revisions to forward-looking
information contained herein to reflect events or circumstances
that occur after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable
securities laws.
Related Links
https://universalibogaine.com
SOURCE Universal Ibogaine Inc.